Literature DB >> 26814363

HLA-A, -B, -C, -DR, and -DQ Matching in Pancreas Transplantation: Effect on Graft Rejection and Survival.

E N Rudolph1, T B Dunn1, D Mauer2, H Noreen2, D E R Sutherland1, R Kandaswamy1, E B Finger1.   

Abstract

To enhance selection of appropriate deceased donors for pancreas transplants, we sought to determine whether HLA matching improved posttransplantation outcomes. In this single-center study of 1219 pancreas transplants, we correlated posttransplantation outcomes with HLA-A, -B, -C, -DR, and -DQ matches and mismatches. Rejection was linearly correlated with the number of mismatches. The individual number of HLA mismatches reached significance at four or more with a 2.3- to 2.9-fold increase in rejection. The effect was most predominant with HLA-B (1.8-fold with one mismatch and 2.0-fold with two mismatches) and -DR (1.9-fold with two mismatches) loci, whereas HLA-A, -C, and -DQ matches or mismatches did not independently predict acute rejection. The affect was strongest in solitary pancreas transplants, with little impact for simultaneous pancreas and kidney (SPK). In contrast, HLA matching did not affect graft or patient survival rates but was associated with a reduced risk of opportunistic infection. Avoidance of acute rejection saved an estimated $32 000 for solitary pancreas recipients and $52 000 for SPK recipients in hospital costs. Our data do not support the use of HLA matching for predicting pancreas graft survival but do support its significance for the reduction of acute rejection, particularly for solitary pancreas recipients. © Copyright 2016 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  clinical research/practice; diabetes: type 1; donors and donation; histocompatibility; major histocompatibility complex (MHC); pancreas/simultaneous pancreas-kidney transplantation; rejection; risk assessment/risk stratification

Mesh:

Substances:

Year:  2016        PMID: 26814363     DOI: 10.1111/ajt.13734

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  6 in total

Review 1.  HLA Mismatching Strategies for Solid Organ Transplantation - A Balancing Act.

Authors:  Andrea A Zachary; Mary S Leffell
Journal:  Front Immunol       Date:  2016-12-07       Impact factor: 7.561

2.  The utility of DLA typing for transplantation medicine in canine models.

Authors:  Keita Sato; Jiro Miyamae; Manabu Sakai; Masaharu Okano; Fumihiko Katakura; Hisashi Shibuya; Tomohiro Nakayama; Tadaaki Moritomo
Journal:  J Vet Med Sci       Date:  2020-07-06       Impact factor: 1.267

3.  Magnitude of Off-Target Allo-HLA Reactivity by Third-Party Donor-Derived Virus-Specific T Cells Is Dictated by HLA-Restriction.

Authors:  Wesley Huisman; Didier A T Leboux; Lieve E van der Maarel; Lois Hageman; Derk Amsen; J H Frederik Falkenburg; Inge Jedema
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

4.  Donor-recipient human leukocyte antigen A mismatching is associated with hepatic artery thrombosis, sepsis, graft loss, and reduced survival after liver transplant.

Authors:  Christopher Bricogne; Neil Halliday; Raymond Fernando; Emmanuel A Tsochatzis; Brian R Davidson; Mark Harber; Rachel H Westbrook
Journal:  Liver Transpl       Date:  2022-05-04       Impact factor: 6.112

5.  Development and validation of a prognostic model for kidney function 1 year after combined pancreas and kidney transplantation using pre-transplant donor and recipient variables.

Authors:  Katharina S Zorn; Simon Littbarski; Ysabell Schwager; Alexander Kaltenborn; Jan Beneke; Jill Gwiasda; Thomas Becker; Felix Braun; Benedikt Reichert; Jürgen Klempnauer; Harald Schrem
Journal:  Langenbecks Arch Surg       Date:  2018-10-18       Impact factor: 3.445

6.  Risk indices predicting graft use, graft and patient survival in solid pancreas transplantation: a systematic review.

Authors:  Jonathan E H Ling; Timothy Coughlan; Kevan R Polkinghorne; John Kanellis
Journal:  BMC Gastroenterol       Date:  2021-02-23       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.